好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Age-specific Patterns of Healthcare Utilization in NMOSD
Autoimmune Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
1-004

Evaluate for age-specific patterns in healthcare utilization among pediatric, young adult, and adult patients with neuromyelitis optica spectrum disorder (NMOSD).  

NMOSD is a relapsing demyelinating disease with high risk of cumulative neurologic disability if untreated. Lifelong immunotherapy is essential to prevent attacks, but patients may have ongoing neurologic disability and symptoms affecting quality of life. Young adults with chronic disease have shown different patterns of healthcare utilization, and this is an area of needed investigation in NMOSD. 

A retrospective chart review was conducted on patients with NMOSD of all ages diagnosed and actively followed by an autoimmune neurologist at the University of Utah or Primary Children’s Hospital. Demographics and data regarding healthcare utilization were collected. 

28 patients with NMOSD were identified (79% female, 68% white). Median current age of the cohort was 42 years (range 7-78), with a median age of diagnosis of 35 years (range 6-68). Patients of all ages experienced delays in diagnosis, access to an NMOSD specialist, and initiation of treatment. Over the past year, 23% of patients <40y had at least one “no showed” appointment, 54% did not have follow up for NMOSD in the planned time frame, and 38% had not pursued referral and/or symptomatic treatment recommendations. In contrast, missed or delayed appointments and referrals were rare in patients ages 40 or older.  

Delays in diagnosis, access to an NMOSD specialist, and treatment initiation were common across all age groups. In patients <40y, over half had delayed follow up. Young patients with NMOSD may be at risk for unique challenges related to healthcare utilization, and understanding these patterns may help develop targeted interventions to improve care. 

 

Authors/Disclosures
Melissa A. Wright, MD (University of Utah)
PRESENTER
Dr. Wright has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis .
Ka-Ho Wong (U of U Neurology Clinic) The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Yibing Zhang, MD Dr. Zhang has nothing to disclose.
Tracy E. Schaffer, RN (University of Utah) Mrs. Schaffer has nothing to disclose.
Regina Farley, RN Ms. Farley has nothing to disclose.
Tammy L. Smith, MD, PhD (Imaging and Neurosciences Center) Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. Smith has received research support from Alexion/AstraZeneca.
John W. Rose, MD, FAAN (Imaging and Neurosciences Center) The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Stacey Clardy, MD, PhD, FAAN (University of Utah) Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Clardy has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from NIH/NINDS. The institution of Dr. Clardy has received research support from SRNA. The institution of Dr. Clardy has received research support from Alexion/AstraZeneca. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Travel/Lodging/Honoraria with U of Iowa, Miami, Stanford, Barrow, Beaumont Health, CCF, Emory, Penn State, Mayo Clinic, Walter Reed.